Diaz-delCastillo Marta, Kamstrup Danna, Olsen Rikke Brix, Hansen Rie Bager, Pembridge Thomas, Simanskaite Brigita, Jimenez-Andrade Juan Miguel, Lawson Michelle A, Heegaard Anne-Marie
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark.
Department of Oncology & Metabolism University of Sheffield Sheffield UK.
JBMR Plus. 2019 Dec 30;4(2):e10252. doi: 10.1002/jbm4.10252. eCollection 2020 Feb.
Bone pain is a serious and debilitating symptom of multiple myeloma (MM) that impairs the quality of life of patients. The underlying mechanisms of the pain are unknown and understudied, and there is a need for immunocompetent preclinical models of myeloma-induced bone pain. The aim of this study was to provide the first in-depth behavioral characterization of an immunocompetent mouse model of MM presenting the clinical disease features: osteolytic bone disease and bone pain. We hypothesized that a widely used syngeneic model of MM, established by systemic inoculation of green fluorescent protein-tagged myeloma cells (5TGM1-GFP) in immunocompetent C57Bl/KaLwRijHsd (BKAL) mice, would present pain-related behaviors. Disease phenotype was confirmed by splenomegaly, high serum paraprotein, and tumor infiltration in the bone marrow of the hind limbs; however, myeloma-bearing mice did not present pain-related behaviors or substantial bone disease. Thus, we investigated an alternative model in which 5TGM1-GFP cells were directly inoculated into the intrafemoral medullary cavity. This localized myeloma model presented the hallmarks of the disease, including high serum paraprotein, tumor growth, and osteolytic bone lesions. Compared with control mice, myeloma-bearing mice presented myeloma-induced pain-related behaviors, a phenotype that was reversed by systemic morphine treatment. Micro-computed tomography analyses of the myeloma-inoculated femurs showed bone disease in cortical and trabecular bone. Repeated systemic bisphosphonate treatment induced an amelioration of the nociceptive phenotype, but did not completely reverse it. Furthermore, intrafemorally injected mice presented a profound denervation of the myeloma-bearing bones, a previously unknown feature of the disease. This study reports the intrafemoral inoculation of 5TGM1-GFP cells as a robust immunocompetent model of myeloma-induced bone pain, with consistent bone loss. Moreover, the data suggest that myeloma-induced bone pain is caused by a combinatorial mechanism including osteolysis and bone marrow denervation. © 2019 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
骨痛是多发性骨髓瘤(MM)的一种严重且使人衰弱的症状,会损害患者的生活质量。疼痛的潜在机制尚不清楚且研究不足,因此需要具有免疫活性的骨髓瘤诱导性骨痛临床前模型。本研究的目的是首次对呈现临床疾病特征(溶骨性骨病和骨痛)的具有免疫活性的MM小鼠模型进行深入的行为特征描述。我们假设,通过在具有免疫活性的C57Bl/KaLwRijHsd(BKAL)小鼠中全身接种绿色荧光蛋白标记的骨髓瘤细胞(5TGM1-GFP)建立的一种广泛使用的MM同基因模型会呈现出与疼痛相关的行为。通过脾肿大、高血清副蛋白以及后肢骨髓中的肿瘤浸润证实了疾病表型;然而,携带骨髓瘤的小鼠并未表现出与疼痛相关的行为或严重的骨病。因此,我们研究了另一种模型,即将5TGM1-GFP细胞直接接种到股骨髓腔内。这种局部骨髓瘤模型呈现出该疾病的特征,包括高血清副蛋白、肿瘤生长和溶骨性骨病变。与对照小鼠相比,携带骨髓瘤的小鼠呈现出骨髓瘤诱导的与疼痛相关的行为,这种表型可通过全身吗啡治疗逆转。对接种骨髓瘤的股骨进行的微计算机断层扫描分析显示皮质骨和小梁骨存在骨病。重复进行全身双膦酸盐治疗可改善伤害感受性表型,但并未完全逆转。此外,股内注射的小鼠呈现出携带骨髓瘤骨骼的严重去神经支配,这是该疾病此前未知的一个特征。本研究报告了将5TGM1-GFP细胞股内接种作为一种强大的具有免疫活性的骨髓瘤诱导性骨痛模型,伴有持续的骨质流失。此外,数据表明骨髓瘤诱导的骨痛是由包括骨溶解和骨髓去神经支配在内的组合机制引起的。© 2019作者。由Wiley Periodicals, Inc.代表美国骨与矿物质研究学会出版。